COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: EBRO FOODS. EUROPA: SANOFI. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’25 que se publicarán en España y Europa en los próximos días. Europa se recupera de las dudas geopolíticas Las bolsas europeas se recuperaron con fuerza al disiparse la amenaza arancelaria tras el anuncio de D. Trump de un “acue...
Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis Sanofi's amlitelimab confirms its potential in atopic dermatitis In the SHORE phase 3 study, amlitelimab in combination with topical therapies met all primary and key secondary endpoints at Week 24 with efficacy progressively increasing throughout the treatment period with some patients improving as early as Week 2In the COAST 2 phase 3 study, amlitelimab demonstrated statistically significant efficacy on vIGA-AD 0/1, the primary endpoint as assessed for the US and US reference countries, and confirmed COAST 1...
Communiqué de presse : L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique Dans l'étude de phase 3 SHORE, l'amlitelimab en association avec des traitements topiques a atteint tous les critères d'évaluation principaux et secondaires clés à la semaine 24, avec une efficacité augmentant progressivement tout au long de la période de traitement, certains patients montrant une amélioration dès la semaine 2Dans l'étude de phase 3 COAST 2, l'amlitelimab a démontré une efficacité statistiquement signific...
A director at Solvay SA bought 1,000 shares at 24.900EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Participation notifications by Morgan Stanley Press release Regulated information Brussels, January 20, 2026, 17:45 CET In line with Belgian transparency legislation (Law of May 2, 2007), Morgan Stanley recently sent to Solvay the following transparency notifications indicating that they crossed the threshold of 3%. Here is a summary of the notifications: Date on which the threshold is crossedVoting rights after the transactionEquivalent financial instruments after the transactionTotalDecember 23, 20250.00%-0.00%January 9,...
Notifications de participation par Morgan Stanley Communiqué de presse Information réglementée Bruxelles, le 20 janvier 2026 - 17h45 CET Conformément à la législation et réglementation en matière de transparence financière (loi du 2 mai 2007), Morgan Stanley a envoyé récemment à Solvay les notifications de transparence suivante indiquant avoir franchi le seuil de 3%. Voici un résumé des notifications: Date de dépassement de seuilDroits de voteInstruments financiers équivalentsTotal23 décembre 20250,00%-0,00%9 janvier 20260,04%3,16%...
Participatiemeldingen van Morgan Stanley Persbericht Gereglementeerde informatie Brussel, 20 januari 2026 - 17u45 CET In overeenstemming met de Belgische transparantiewetgeving (Wet van 2 mei 2007) heeft Morgan Stanley onlangs de volgende transparantiekennisgevingen naar Solvay gestuurd om aan te geven dat ze de drempel van 3% heeft overschreden. Hier is een samenvatting van de bewegingen: Datum waarop de drempel werd overschredenStemrechtenAan stemrechten gelijkgestelde financiële instrumentenTotaal23 december 20250,00%-0,00%9 ja...
Heineken Holding N.V. reports transactions under its current share buyback programme Heineken Holding N.V. reports transactions under its current share buyback programme Amsterdam, 19 January 2026 - Heineken Holding N.V. (EURONEXT:HEIO; OTCQX: HKHHY), hereby reports transaction details related to the first tranche of up to circa €375 million tranche of its share buyback programme of up to circa €750 million as communicated on 12 February 2025. From 12 January 2026 up to and including 16 January 2026 a total of 159,495 shares were repurchased on exchange at an average price of € 61.08. ...
Press Release: Myqorzo and Redemplo approved in China Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndromeUnderscores Sanofi’s long-term commitment to China, reinforcing the ambition to provide transformative medicines to patients in disease areas with large unmet medical needs Paris, January 15, 2026. The National Medical Products Administration in China has approved two Sanofi-licensed innovative medicines, Myqorzo (aficamten) for the treatment of obstructive hypertrophic cardiomyopathy ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.